Samchundang Pharm


Concise Prescribing Info
Ceftazidime pentahydrate
Susceptible infections caused by gm +ve & gm -ve organisms. Sepsis & meningitis. Pneumonia, pleuritis, empyema, pulmonary abscess, bronchiectasis (in infection), bronchitis & pulmonary infection in patients w/ cystic fibrosis. Otitis media, malignant external otitis, mastoiditis, sinusitis, severe infection in ear or throat part. Pyelonephritis, prostatitis, cystitis & urethritis. Erysipelas, abscess, secondary infection after trauma or burn, mastitis & dermal ulcer. Cholangitis, cholecystitis, empyema of gallbladder, intra-abdominal abscess, peritonitis, diverticulitis, enterocolitis, pelvic infection. Osteomyelitis, ostitis, septic arthritis, infectious bursitis. Severe infections in the immunocompromised patient, severe infection including burn infection, infection due to hemodialysis or intraperitoneal dialysis, infection associated w/ CAPD.
Dosage/Direction for Use
IV/IM Adult 0.5-2 g bid or tid. Most infections 1 g 8 hrly or 2 g 12 hrly. UTI or moderate infections 0.5-1 g 12 hrly. Very severe infections particularly in immunocompromised patient including those w/ neutropenia 2 g 8-12 hrly. Cystic fibrosis Fibrocystic adult w/ pseudomonal lung infections 100-150 mg/kg/day in 3 divided doses. Normal renal function 9 g/day. Childn & infant (≥2 mth) 30-100 mg/kg/day in 2 or 3 divided doses. Infected immunocompromised, fibrocystic or w/ meningitis 150 mg/kg/day (Max: 6 g/day) in 3 divided doses. Neonate 0-2 mth 25-60 mg/kg/day in 2 divided doses. Elderly (>80 yr) Max: 3 g daily. Renal impairment Initial loading dose: 1 g. Maintenance doses: CrCl 31-50 mL/min 1 g 12 hrly; 16-30 mL/min 1 g 24 hrly; 6-15 mL/min 0.5 g 24 hrly; <5 mL/min 0.5 g 48 hrly.
Hypersensitivity to cephalosporins, penicillin-group antibiotics or β-lactam antibiotics. Patients w/ known shock; susceptible to allergic reactions eg, bronchial asthma, eruption & urticaria; severe renal disorder; those who cannot ingest orally or parenteral patients, elderly patients, patients w/ systemic bad condition.
Special Precautions
Discontinue immediately if allergic reaction occurs. Perform skin & susceptibility tests prior to therapy. Prolonged use may result in overgrowth of insusceptible bacteria. reduced dose in patient w/ renal disorder. False +ve results in urine glucose tests using Benedict's reagent, Clinitest, Fehling's soln; +ve direct Coombs' test. May interfere w/ creatinine test using picrate alkali method. Pregnancy & lactation. Elderly. Premature & newborn.
Adverse Reactions
Occasionally, nausea, vomiting, diarrhea; granulocytopenia, eosinophilia, thrombocytosis; headache, dizziness; elevation in liver enzyme value eg, ALT, AST, ALP, LDH or GGT; transient elevation of urea in blood, BUN & serum creatinine; vaginitis; phlebitis & thrombotic phlebitis in IV inj; pain & inflammation in IM inj. Rarely, shock.
Drug Interactions
Renal disorder may be increased w/ high doses of antibiotics eg, aminoglycosides or diuretics eg, furosemide. Possible counteraction w/ chloramphenicol. May reduce reabsorption rate of estrogen or effect of OCs.
MIMS Class
ATC Classification
J01DD02 - ceftazidime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Tazidem powd for inj 1 g
1's (P1,155/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in